Zhang Y - Search Results

1

Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020.

Wei Y, Zhang Y, Xu Z, Wang G, Zhou Y, Li H, Shi L, Naci H, Wagner AK, Guan X. Wei Y, et al. Among authors: zhang y. Lancet Reg Health West Pac. 2024 Apr 2;45:101055. doi: 10.1016/j.lanwpc.2024.101055. eCollection 2024 Apr. Lancet Reg Health West Pac. 2024. PMID: 38590780 Free PMC article.

2

Differences in reimbursement listing of anticancer therapies in China: an observational study.

Guan X, Zhang Y, Wushouer H, Shi L, Ross-Degnan D, Wagner AK. Guan X, et al. Among authors: zhang y. BMJ Open. 2020 Jan 6;10(1):e031203. doi: 10.1136/bmjopen-2019-031203. BMJ Open. 2020. PMID: 31911513 Free PMC article.

3

Physician patient-sharing relationships and healthcare costs and utilization in China: social network analysis based on health insurance data.

Hu H, Zhang Y, Zhu D, Guan X, Shi L. Hu H, et al. Among authors: zhang y. Postgrad Med. 2021 Sep;133(7):798-806. doi: 10.1080/00325481.2021.1944650. Epub 2021 Jun 28. Postgrad Med. 2021. PMID: 34139934

4

The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.

Zhang Y, Wushouer H, Han S, Fu M, Guan X, Shi L, Wagner A. Zhang Y, et al. BMJ Glob Health. 2021 Jul;6(7):e006196. doi: 10.1136/bmjgh-2021-006196. BMJ Glob Health. 2021. PMID: 34266848 Free PMC article.

5

Childhood cancer drugs in China: An overview and comparison of regulatory approvals in China and the United States.

Zhang Y, Katharina Wagner A, Du H, Han T, Gupta S, Denburg AE, Frazier AL, Guan X, Shi L. Zhang Y, et al. Int J Cancer. 2022 Feb 1;150(3):482-490. doi: 10.1002/ijc.33818. Epub 2021 Oct 6. Int J Cancer. 2022. PMID: 34536294 Review.

6

Misleading Reporting in Statistically Not Significant Oncology Trials-Joining Efforts Toward Unbiased Results Interpretation.

Zhang Y, Guan X. Zhang Y, et al. JAMA Netw Open. 2021 Dec 1;4(12):e2138695. doi: 10.1001/jamanetworkopen.2021.38695. JAMA Netw Open. 2021. PMID: 34874408 Free article. No abstract available.

7

Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.

Zhang Y, Wei Y, Li H, Chen Y, Guo Y, Han S, Shi L, Guan X. Zhang Y, et al. Pharmacoeconomics. 2022 Jul;40(7):715-724. doi: 10.1007/s40273-022-01161-7. Epub 2022 Jun 29. Pharmacoeconomics. 2022. PMID: 35764914 Free PMC article.

8

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.

Zhang Y, Naci H, Wagner AK, Xu Z, Yang Y, Zhu J, Ji J, Shi L, Guan X. Zhang Y, et al. JAMA Netw Open. 2022 Aug 1;5(8):e2225973. doi: 10.1001/jamanetworkopen.2022.25973. JAMA Netw Open. 2022. PMID: 35947385 Free PMC article.

9

Newly approved cancer drugs in China - innovation and clinical benefit.

Zhang Y, Wagner AK, Guan X. Zhang Y, et al. Nat Rev Clin Oncol. 2023 Mar;20(3):135-136. doi: 10.1038/s41571-023-00728-3. Nat Rev Clin Oncol. 2023. PMID: 36646814 No abstract available.

10

Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011-2021.

Bai L, Zhan Y, Zhou Y, Zhang Y, Shi L, Gupta S, Denburg A, Guan X. Bai L, et al. Among authors: zhang y. EClinicalMedicine. 2023 Apr 12;59:101966. doi: 10.1016/j.eclinm.2023.101966. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37125406 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

262,680 results

Search Page

Filters